nheath+FollowModerna’s New Covid Shot: What’s the Deal?Moderna just scored FDA approval for a new Covid vaccine, but there’s a catch—it’s only for folks 65+ or those 12-64 with health risks. The new shot, mNexspike, uses just a fifth of the dose of their old vaccine but still packs a punch. It’s not replacing the OG shot, just giving high-risk people another option. Basically, it’s a big move for next-gen vaccines, but don’t expect to see it everywhere just yet! #CovidVaccine #Moderna #FDA #Health1518Share
Allison Bauer+FollowNovavax’s Big FDA Win Sends Shares SoaringNovavax just got its COVID shot fully approved by the FDA, making it the only non-mRNA option in the US—and investors are loving it. The stock popped over 20%! This is a huge move, especially with vaccine access in the spotlight lately. Meanwhile, solar stocks are taking a hit as lawmakers threaten to cut clean energy tax credits, and China’s not happy about new US chip restrictions. Wild day in the markets! #Novavax #FDAApproval #StockMarket #CovidVaccine #SolarStocks #Health00Share
nheath+FollowNew Covid Shot, But Only for SomeThe FDA just greenlit a new Covid vaccine from Novavax, but here’s the catch: it’s only for people 65+ or those 12-65 with health risks. Unlike the usual mRNA shots, this one’s protein-based—so if you’ve been holding out for something different, this might be your moment (if you qualify). People are already debating the restrictions and whether it should be more widely available. Would you try this new option if you could? #CovidVaccine #Novavax #FDA #HealthNews #VaccineUpdate #Health322Share
